Eliminating Drug Co-Payments Leads to Savings

A Geisinger study published in the February 2016 issue of the American Journal of Managed Care shows that instituting a zero prescription co-pay for Geisinger’s chronically ill employee population resulted in a positive cost saving and return on investment. Results of the Geisinger study indicate that a zero co-pay drug program was associated with positive cost savings and a return on investment of 1.8 over five years.